SG10201810016XA - Methods of treating depression using nmda modulators - Google Patents

Methods of treating depression using nmda modulators

Info

Publication number
SG10201810016XA
SG10201810016XA SG10201810016XA SG10201810016XA SG10201810016XA SG 10201810016X A SG10201810016X A SG 10201810016XA SG 10201810016X A SG10201810016X A SG 10201810016XA SG 10201810016X A SG10201810016X A SG 10201810016XA SG 10201810016X A SG10201810016X A SG 10201810016XA
Authority
SG
Singapore
Prior art keywords
methods
treating depression
nmda modulators
depression
nmda
Prior art date
Application number
SG10201810016XA
Other languages
English (en)
Inventor
Ron Burch
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of SG10201810016XA publication Critical patent/SG10201810016XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SG10201810016XA 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators SG10201810016XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14

Publications (1)

Publication Number Publication Date
SG10201810016XA true SG10201810016XA (en) 2018-12-28

Family

ID=55304631

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810016XA SG10201810016XA (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators
SG11201701134XA SG11201701134XA (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701134XA SG11201701134XA (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Country Status (18)

Country Link
US (1) US20170296616A1 (enrdf_load_stackoverflow)
EP (1) EP3180015A4 (enrdf_load_stackoverflow)
JP (2) JP2017524721A (enrdf_load_stackoverflow)
KR (1) KR20170040351A (enrdf_load_stackoverflow)
CN (1) CN106659763A (enrdf_load_stackoverflow)
AU (2) AU2015301650A1 (enrdf_load_stackoverflow)
BR (1) BR112017002930A2 (enrdf_load_stackoverflow)
CA (1) CA2957937A1 (enrdf_load_stackoverflow)
CL (1) CL2017000378A1 (enrdf_load_stackoverflow)
CO (1) CO2017002356A2 (enrdf_load_stackoverflow)
IL (1) IL250557A0 (enrdf_load_stackoverflow)
MX (1) MX2017002052A (enrdf_load_stackoverflow)
PH (1) PH12017500275A1 (enrdf_load_stackoverflow)
RU (1) RU2017107033A (enrdf_load_stackoverflow)
SG (2) SG10201810016XA (enrdf_load_stackoverflow)
UA (1) UA123623C2 (enrdf_load_stackoverflow)
WO (1) WO2016025721A1 (enrdf_load_stackoverflow)
ZA (1) ZA201701526B (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016340080A1 (en) * 2015-10-16 2018-05-10 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
WO2018098344A1 (en) * 2016-11-28 2018-05-31 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
EP3641742A2 (en) * 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
EP3706734A1 (en) * 2017-11-10 2020-09-16 Naurex Inc. Methods of administration of nmda receptor agonists
CN111670041A (zh) * 2017-12-05 2020-09-15 诺雷克斯股份有限公司 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
PL2985032T3 (pl) * 2009-10-05 2019-07-31 Northwestern University Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Also Published As

Publication number Publication date
ZA201701526B (en) 2018-05-30
MX2017002052A (es) 2018-08-15
US20170296616A1 (en) 2017-10-19
UA123623C2 (uk) 2021-05-05
RU2017107033A (ru) 2018-09-14
JP2020128391A (ja) 2020-08-27
CL2017000378A1 (es) 2017-11-03
AU2020203165A1 (en) 2020-06-04
BR112017002930A2 (pt) 2017-12-05
CO2017002356A2 (es) 2017-06-09
SG11201701134XA (en) 2017-03-30
PH12017500275A1 (en) 2017-07-03
IL250557A0 (en) 2017-03-30
EP3180015A4 (en) 2018-02-14
WO2016025721A1 (en) 2016-02-18
CN106659763A (zh) 2017-05-10
RU2017107033A3 (enrdf_load_stackoverflow) 2019-02-12
JP2017524721A (ja) 2017-08-31
KR20170040351A (ko) 2017-04-12
CA2957937A1 (en) 2016-02-18
AU2015301650A1 (en) 2017-03-23
EP3180015A1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12017500275A1 (en) Methods of treating depression using nmda modulators
IL252957A0 (en) An implantable ultrasound generating device for brain therapy, a device containing this device and a method for inserting this device
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
GB2541571A (en) Pharmaceutical compositions
IL274855A (en) Device, systems and methods for dental treatments
NZ630757A (en) Self-optimising respiratory therapy system
SG10201900574SA (en) Virtual currency conversion device, method and computer program
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
IL243707A0 (en) Treatment to regulate the microbiota in the intestine
MX2017003797A (es) Macrociclos peptidomimeticos y usos de los mismos.
EP3087941A4 (en) Therapeutic treatment system, and operating method for therapeutic treatment system
MX2017002489A (es) Agentes terapeuticos humanos.
IL271728A (en) Materials, uses and treatment methods
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EP3122296A4 (en) Ophthalmic treatment solution delivery devices and delivery augmentation methods
MX2017000306A (es) Metodos para tratar hipotension.
ZA201703467B (en) Methods of treating ocular conditions
MX2016009537A (es) Metodo para tratar ropa.
EP3166329A4 (en) White noise generating headset for stress relaxation and concentration improvement, and white noise generating method using same
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
GB2539742B (en) Therapeutic treatment methods, and apparatus for use therein
ZA201703222B (en) Magnetic field therapy apparatus, and method for generating a magnetic field
MX2016009541A (es) Metodo para tratar vajilla.